DCGI approves trials for Bharat Biotech's nasal covid booster in India
The Drugs Controller General of India (DCGI) has approved Bharat Biotech's intranasal Covid booster dosage studies in India. The drops will be tested in nine different places around the country. Bharat Biotech recently requested approval from the DCGI to deliver the Omicran diffusion vaccine as a booster dose and to perform clinical studies.
Bharat Biotech aims to perform these clinical studies on approximately 5,000 volunteers, according to information obtained. According to reports, half of them are receiving Covaxin and the other half are receiving Covishield vaccination. It is widely stated that taking a booster dosage after 6 to 9 months of the second dose has a better advantage.